SCHEMBL4055085

SCHEMBL4055085

COc1cc(CCc2nc3ncc(-c4ccco4)cc3[nH]2)cc(OC)c1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 4/20 0.48
NOS2 P35228 4/20 0.48
NOS3 P29474 3/20 0.48
TUBB4A P04350 5/20 0.46
TUBB P07437 5/20 0.46
TUBA3C P0DPH7 5/20 0.46
TUBA1B P68363 5/20 0.46
TUBA4A P68366 5/20 0.46
TUBB4B P68371 5/20 0.46
TUBB3 Q13509 5/20 0.46
TUBB2A Q13885 5/20 0.46
TUBB8 Q3ZCM7 5/20 0.46
TUBA3E Q6PEY2 5/20 0.46
TUBA1A Q71U36 5/20 0.46
TUBA1C Q9BQE3 5/20 0.46
TUBB6 Q9BUF5 5/20 0.46
TUBB2B Q9BVA1 5/20 0.46
TUBB1 Q9H4B7 5/20 0.46
MAPT P10636 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4052694 0.91 TUBB4A (0.52) NOS1NOS2NOS3TUBB4ATUBB
SCHEMBL4062481 0.90 NOS3 (0.48) NOS1NOS2NOS3MAPTTSHR
SCHEMBL4055769 0.86 NOS1 (0.54) NOS1NOS2NOS3MAPTTSHR
SCHEMBL4055542 0.85 NOS1 (0.51) NOS1NOS2NOS3SMPD3CYP2C9
SCHEMBL4058711 0.84 NOS3 (0.62) NOS1NOS2NOS3TUBB4ATUBB
SCHEMBL4050818 0.84 NOS1 (0.55) NOS1NOS2NOS3TSHRCYP2C9
SCHEMBL13608704 0.84 TUBB4A (0.44) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL4060650 0.83 NOS3 (0.49) NOS1NOS2NOS3MAPTSIRT1
SCHEMBL4054350 0.83 POLB (0.52) NOS1NOS2NOS3TUBB4ATUBB
SCHEMBL4058313 0.82 NOS1 (0.44) NOS1NOS2NOS3MAPTNTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NOS1 879/4885NOS2 1019/4885NOS3 907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.